Fintel reports that on January 31, 2025, JMP Securities initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a Market Outperform recommendation. Analyst Price Forecast Suggests 219.11% ...

Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on ...

JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...

JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV).Invest with Confidence: ...

Analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of KalVista Pharmaceuticals in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P.

Filament Health Corp.  (Cboe CA: FH) ("Filament" or the "Company"), a clinical?stage natural psychedelic drug development company, today announced that it has shipped its botanical psilocybin drug ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...

DRI Healthcare Trust is also making a $5 million investment in KalVista KalVista is based in Cambridge, Massachusetts, and developed Sebetralstat as an oral on-demand therapy for treating attacks ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Read Our Latest Analysis on KalVista Pharmaceuticals KalVista Pharmaceuticals Trading Up 6.2 % Shares of NASDAQ KALV opened at $7.86 on Thursday. The stock has a market cap of $388.43 million, a ...